Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Dosing Reference: Trulicity vs Retatrutide | Parameter | Trulicity (Dulaglutide) | Retatrutide | |---|---|---| | Route | Subcutaneous, once weekly | Subcutaneous, once weekly | | Starting dose | 0.75 mg | 2 mg (Phase 2 protocol) | | Maximum dose | 4.5 mg | 12 mg (Phase 2) | | Titration interval | Every 4 weeks | Every 4 weeks | | Approved indication | T2D, CV risk reduction | Not approved (Phase 3) | | Storage | Refrigerated or room temp (up to 14 days) | Refrigerated (Phase 2 trial supply) | | Pen device | Single-dose autoinjector | Single-dose autoinjector (trial formulation) | What the Guidelines Currently Say The ADA 2024 Standards of Care recommend GLP-1 receptor agonists with proven cardiovascular benefit as preferred second-line agents after metformin in patients with type 2 diabetes and atherosclerotic cardiovascular disease [4]
Call (973) 803-5515 Today
Thuc c gi bn khong 2.200.000 ng
Experiences fatigue that does not have an obvious cause, nerve pain or anaemia, and B12 tests are found to be low
For example, iron deficiency anaemia happens when the body does not contain enough iron
The right choice depends on your individual health, goals, and how your body responds to treatment
